興科蓉醫藥(06833.HK)斥5,300萬人幣研發私密針及私密針聚己內酯填充材料
興科蓉醫藥(06833.HK)公布,其間接全資附屬四川興科蓉與北京諾康達訂立私密針技術開發協議,以合作為公司研發私密針及私密針聚己內酯填充材料,代價為5,300萬元人民幣。
公司認為,私密針技術開發協議項下有關交易可為集團提供基礎,建立專長及資源以設立自主研發中心,以逐步開發、生產及銷售醫療美容產品。此外,集團完善的醫藥營銷渠道將為該等新醫療美容產品的推廣帶來協同效應,讓集團可實現長期收益增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.